New drug combo aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT05846867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two immunotherapy drugs, AK119 and AK112, alone or with chemotherapy, in 170 people with a common type of colorectal cancer (pMMR/MSS). The goal is to see if these combinations shrink tumors and are safe. The trial is active but not recruiting new participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK119 and AK112 (immunotherapy drugs) with or without chemotherapy (oxaliplatin, irinotecan, calcium folinate, fluorouracil)
- What this could lead to
- If successful, this could offer a new treatment option for people with a common type of colorectal cancer that is hard to treat.
- What could go wrong
- This is an early-phase trial (Phase Ib/II) with a small number of participants, so results may not apply to everyone. The drugs may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Affiliated to Harbin Medical University
Harbin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?